AgingResearch.NewsJoin free

SCYNEXIS

CompanyUnited StatesFounded 1999

Wikidata

SCYNEXIS develops one asset, in phase 1 (SCY-770 in autosomal dominant polycystic kidney disease). Mostly small molecule acting on AMPK signalling, PRKAA1 and PRKAA2; based in the United States, founded in 1999.

1
Asset
Furthest stage
Phase 1
0
Trials
0
Signals

Pipeline

1

  • SCY-770

    Direct activator of AMP-activated protein kinase (AMPK)

    Phase 1, Small molecule, AMPK signalling, PRKAA1, autosomal dominant polycystic kidney disease

Full company profiles: pipeline, trials, funding and people.

See Pro

In the full profile

  • Evidence behind the mechanisms3
  • Deals1
  • Similar companies6

Intelligence